Heterocycles in drugs and drug discovery

被引：511

作者：

Gomtsyan, A. ^{[1
]}

机构：

[1] Abbott Labs, Global Pharmaceut Res & Dev, Neurosci Res, Abbott Pk, IL 60064 USA

来源：

CHEMISTRY OF HETEROCYCLIC COMPOUNDS | 2012年 / 48卷 / 01期

关键词：

bioisosteres; ClogP; drug discovery; heterocycles; hydrogen bonding; lipophilicity; polarity; PSA; TPSA; DESIGN;

D O I：

10.1007/s10593-012-0960-z

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

Heterocycles are common fragments of the vast majority of marketed drugs. This is a reflection of the central role that heterocycles play in modern drug design. They can serve as useful tools to manipulate lipophilicity, polarity, and hydrogen bonding capacity of molecules, which may lead to improved pharmacological, pharmacokinetic, toxicological, and physicochemical properties of drug candidates and ultimately drugs.

引用

页码：7 / 10

页数：4

共 9 条

[1] A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif [J].

Kalgutkar, Amit S. ;

Driscoll, James ;

Zhao, Sabrina X. ;

Walker, Gregory S. ;

Shepard, Richard M. ;

Soglia, John R. ;

Atherton, James ;

Yu, Linning ;

Mutlib, Abdul E. ;

Munchhof, Michael J. ;

Reiter, Lawrence A. ;

Jones, Christopher S. ;

Doty, Johnathan L. ;

Trevena, Kristen A. ;

Shaffer, Christopher L. ;

Ripp, Sharon L. .

CHEMICAL RESEARCH IN TOXICOLOGY, 2007, 20 (12) :1954-1965

[2] The pKBHX Database: Toward a Better Understanding of Hydrogen-Bond Basicity for Medicinal Chemists [J].

Laurence, Christian ;

Brameld, Ken A. ;

Graton, Jerome ;

Le Questel, Jean-Yves ;

Renault, Eric .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (14) :4073-4086

[3] Design of a series of bicyclic HIV-1 integrase inhibitors. Part 2: Azoles: Effective metal chelators [J].

Le, Giang ;

Vandegraaff, Nick ;

Rhodes, David I. ;

Jones, Eric D. ;

Coates, Jonathan A. V. ;

Thienthong, Neeranat ;

Winfield, Lisa J. ;

Lu, Long ;

Li, Xinming ;

Yu, Changjiang ;

Feng, Xiao ;

Deadman, John J. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (19) :5909-5912

[4] Reducing the Risk of Drug Attrition Associated with Physicochemical Properties [J].

Leeson, Paul D. ;

Empfield, James R. .

ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 45, 2010, 45 :393-407

[5] Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: Identification of a tetrazole-containing inhibitor with cellular activity [J].

Liljebris, C ;

Larsen, SD ;

Ogg, D ;

Palazuk, BJ ;

Bleasdale, JE .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (09) :1785-1798

[6] Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings [J].

Lipinski, CA ;

Lombardo, F ;

Dominy, BW ;

Feeney, PJ .

ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) :3-25

[7] Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design [J].

Meanwell, Nicholas A. .

JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (08) :2529-2591

[8] Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties [J].

Wager, Travis T. ;

Hou, Xinjun ;

Verhoest, Patrick R. ;

Villalobos, Anabella .

ACS CHEMICAL NEUROSCIENCE, 2010, 1 (06) :435-449

[9] Lipophilicity in drug discovery [J].

Waring, Michael J. .

EXPERT OPINION ON DRUG DISCOVERY, 2010, 5 (03) :235-248

← 1 →